CoChat

Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab

Open access
Kurdi, Ahmed T., Glavey, Siobhan V., Bezman, Natalie A., Jhatakia, Amy, Guerriero, Jennifer L., Manier, Salomon, Moschetta, Michele, Mishima, Yuji, Roccaro, Aldo, Detappe, Alexandre, Liu, Chia-Jen, Sacco, Antonio, Huynh, Daisy, Tai, Yu-Tzu, Robbins, Michael D., Azzi, Jamil, Ghobrial, Irene M. · 2018 · Molecular Cancer Therapeutics
Cited by 97

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Elotuzumab, a recently approved antibody for the treatment of multiple myeloma, has been shown to stimulate Fcγ receptor (FcγR)-mediated antibody-dependent cellular cytotoxicity by natural killer (NK) cells toward myeloma cells. The modulatory effects of elotuzumab on other effector cells in the tumor microenvironment, however, has not been fully explored. Antibody-dependent cellular phagocytosis (ADCP) is a mechanism by which macrophages contribute to antitumor potency of monoclonal antibodies. Herein, we studied the NK cell independent effect of elotuzumab on tumor-associated macrophages using a xenograft tumor model deficient in NK and adaptive immune cells. We demonstrate significant antitumor efficacy of single-agent elotuzumab in immunocompromised xenograft models of multiple myeloma, which is in part mediated by Fc–FcγR interaction of elotuzumab with macrophages. Elotuzumab is shown in this study to induce phenotypic activation of macrophages in vivo and mediates ADCP of myeloma cells though a FcγR-dependent manner in vitro. Together, these findings propose a novel immune-mediated mechanism by which elotuzumab exerts anti-myeloma activity and helps to provide rationale for combination therapies that can enhance macrophage activity. Mol Cancer Ther; 17(7); 1454–63. ©2018 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-17-0998

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 97

Metadata

Authors
Kurdi, A. T., Glavey, S. V., Bezman, N. A., Jhatakia, A., Guerriero, J. L., Manier, S., Moschetta, M., Mishima, Y., Roccaro, A., Detappe, A., Liu, C.-J., Sacco, A., Huynh, D., Tai, Y.-T., Robbins, M. D., Azzi, J., & Ghobrial, I. M.
Venue
Molecular Cancer Therapeutics
Published
2018-07-01
Volume
17
Issue
7
Pages
1454-1463
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2796970920
Cited by
97
References
9
FWCI
6.53
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. https://app.cochat.ai/papers/10.1158/1535-7163.mct-17-0998
The paper
Kurdi, A. T., Glavey, S. V., Bezman, N. A., Jhatakia, A., Guerriero, J. L., Manier, S., Moschetta, M., Mishima, Y., Roccaro, A., Detappe, A., Liu, C.-J., Sacco, A., Huynh, D., Tai, Y.-T., Robbins, M. D., Azzi, J., & Ghobrial, I. M. (2018). Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-17-0998

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.